New-Onset Status Epilepticus in Pediatric Patients: Causes, Characteristics, and Outcomes
Saba Jafarpour1, Ryan M Hodgeman2, Carolina De Marchi Capeletto3
1Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Insights
New-onset status epilepticus in children, even without prior seizures, carries risks of recurrence, death, and cognitive impairment. Early interventions are crucial for this high-risk pediatric group.
Area of Science:
- Pediatric Neurology
- Epileptology
- Clinical Neuroscience
Background:
- Many pediatric patients experience status epilepticus without a prior seizure history.
- New-onset status epilepticus (NOSE) requires careful characterization in pediatric populations.
Purpose of the Study:
- To analyze the clinical characteristics of pediatric patients with new-onset convulsive status epilepticus.
- To identify risk factors and outcomes associated with NOSE in children and adolescents.
Main Methods:
- Retrospective analysis of pediatric patients (1 month to 21 years) with convulsive status epilepticus and no prior seizure history.
- Definition of new-onset refractory status epilepticus (NORSE) as SE refractory to two treatments without identified cause within 48 hours.
Main Results:
- 17.2% of status epilepticus cases were new-onset (NOSE), with 0.9% being refractory (NORSE).
- Median age was 3.5 years; unknown etiology was common (36.7%).
- Significant cognitive impairment (29.1%) and behavioral problems (20%) were observed post-NOSE, with symptomatic etiology increasing risk.
Conclusions:
- Pediatric patients with NOSE face risks of seizure recurrence, death, and long-term cognitive-behavioral issues.
- This high-risk population may benefit from specialized monitoring and care interventions.
Background:
Many pediatric patients presenting with status epilepticus have no history of seizures.
Methods:
We retrospectively analyzed the clinical characteristics of patients aged one month to 21 years who presented during six consecutive years with convulsive status epilepticus and without a history of seizures. New-onset refractory status epilepticus was defined as status epilepticus refractory to two lines of treatment, without an identified cause in the first 48 hours.
Results:
Of 460 patients with status epilepticus, 79 (17.2%) presented with new-onset status epilepticus, including four (0.9%) with new-onset refractory status epilepticus. Of those patients, 54.4% were female, and the median age was 3.5 years (IQR: 1.08 to 6.75). The median seizure duration was 20 minutes (IQR: 10 to 40 minutes). Etiology was unknown in 36.7%, symptomatic in 30.3%, provoked in 16.5%, and provoked with an existing symptomatic etiology in 16.5%. Patients were followed for a median duration of 63 months (IQR: 21 to 97). The mortality rate was 3.8%. Of 55 patients who were developmentally normal at baseline, 29.1% had a significant cognitive impairment at the last follow-up, and 20% had academic difficulties or behavioral problems. Patients with symptomatic etiology had greater odds of having cognitive and behavioral problems compared with patients with unknown etiology (odds ratio = 3.83, P = 0.012).
Conclusions:
Patients with new-onset status epilepticus are at risk for recurrent seizures, recurrent status epilepticus, death, and subsequent cognitive-behavioral impairment. Specific monitoring and care interventions might be required in this high-risk population.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Characteristics of Life
Predicting Reaction Outcomes


